Literature DB >> 3781911

Clostomicins, new antibiotics produced by Micromonospora echinospora subsp. armeniaca subsp. nov. I. Production, isolation, and physico-chemical and biological properties.

S Omura, N Imamura, R Oiwa, H Kuga, R Iwata, R Masuma, Y Iwai.   

Abstract

A soil isolate named as Micromonospora echinospora subsp. armeniaca subsp. nov. KMR-593 was found to produce at least five related antibiotics, clostomicins, active against Gram-positive bacteria including anaerobes. From the physico-chemical properties, one of these components was identified with lipiarmycin and others were found to be new antibiotics. Each component includes two chlorine atoms and the molecular weights of A and B2, C, and D are 1,058, 1,042 and 1,056, respectively. The structural differences were characterized by NMR analyses.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3781911     DOI： 10.7164/antibiotics.39.1407

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


  12 in total

Review 1.  Thom Award Lecture. Trends in the search for bioactive microbial metabolites.

Authors:  S Omura
Journal:  J Ind Microbiol       Date:  1992-09

Review 2.  Taxonomy, Physiology, and Natural Products of Actinobacteria.

Authors:  Essaid Ait Barka; Parul Vatsa; Lisa Sanchez; Nathalie Gaveau-Vaillant; Cedric Jacquard; Jan P Meier-Kolthoff; Hans-Peter Klenk; Christophe Clément; Yder Ouhdouch; Gilles P van Wezel
Journal:  Microbiol Mol Biol Rev       Date:  2015-11-25       Impact factor: 11.056

3.  Stereostructure of luminamicin, an anaerobic antibiotic, via molecular dynamics, NMR spectroscopy, and the modified Mosher method.

Authors:  Hiroaki Gouda; Toshiaki Sunazuka; Hideaki Ui; Masaki Handa; Yusuke Sakoh; Yuzuru Iwai; Shuichi Hirono; Satoshi Omura
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

Review 4.  Astonishing diversity of natural surfactants: 2. Polyether glycosidic ionophores and macrocyclic glycosides.

Authors:  Valery M Dembitsky
Journal:  Lipids       Date:  2005-03       Impact factor: 1.880

5.  Rufomycins or Ilamycins: Naming Clarifications and Definitive Structural Assignments.

Authors:  Bin Zhou; Prabhakar S Achanta; Gauri Shetye; Shao-Nong Chen; Hyun Lee; Ying-Yu Jin; Jinhua Cheng; Mi-Jin Lee; Joo-Won Suh; Sanghyun Cho; Scott G Franzblau; Guido F Pauli; James B McAlpine
Journal:  J Nat Prod       Date:  2021-10-10       Impact factor: 4.050

6.  In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile.

Authors:  R N Swanson; D J Hardy; N L Shipkowitz; C W Hanson; N C Ramer; P B Fernandes; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 7.  Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.

Authors:  Jennifer A Leeds
Journal:  Cold Spring Harb Perspect Med       Date:  2016-02-01       Impact factor: 6.915

Review 8.  New target for inhibition of bacterial RNA polymerase: 'switch region'.

Authors:  Aashish Srivastava; Meliza Talaue; Shuang Liu; David Degen; Richard Y Ebright; Elena Sineva; Anirban Chakraborty; Sergey Y Druzhinin; Sujoy Chatterjee; Jayanta Mukhopadhyay; Yon W Ebright; Alex Zozula; Juan Shen; Sonali Sengupta; Rui Rong Niedfeldt; Cai Xin; Takushi Kaneko; Herbert Irschik; Rolf Jansen; Stefano Donadio; Nancy Connell; Richard H Ebright
Journal:  Curr Opin Microbiol       Date:  2011-08-19       Impact factor: 7.934

Review 9.  Actinomycetes: A Never-Ending Source of Bioactive Compounds-An Overview on Antibiotics Production.

Authors:  Davide De Simeis; Stefano Serra
Journal:  Antibiotics (Basel)       Date:  2021-04-22

10.  Final Demonstration of the Co-Identity of Lipiarmycin A3 and Tiacumicin B (Fidaxomicin) through Single Crystal X-ray Analysis.

Authors:  Stefano Serra; Luciana Malpezzi; Angelo Bedeschi; Claudio Fuganti; Piera Fonte
Journal:  Antibiotics (Basel)       Date:  2017-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.